Clinical Trial Update: A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

A multicenter randomized double-blind Phase II/III trial evaluating GM1 for prevention of peripheral neuropathy induced by albumin-bound paclitaxel in breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Peripheral Neuropathy

Drugs mentioned

• GM1 (monosialotetrahexosyl ganglioside)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients | Phase 2, Phase 3 | Status: UNKNOWN